Huadong Medicine Achieves Strong Growth with Annual Revenue of ￥40.6 Billion in 2023

Huadong Medicine, a prominent player in the pharmaceutical industry, has recently released its annual report for the year 2023. The company has demonstrated remarkable performance, with a robust increase in revenue across various sectors.

Huadong Medicine's annual report for 2023 reveals impressive financial results, showcasing a significant milestone in the company's growth trajectory. With a year-end revenue of 40.624 billion yuan, Huadong Medicine achieved a notable growth rate of 7.71%. The company's net profit attributable to shareholders reached 2.839 billion yuan, reflecting a substantial increase of 13.59%. Furthermore, the non-recurring net profit attributable to shareholders witnessed a growth of 13.55% to reach 2.737 billion yuan.

The pharmaceutical industry emerged as a key driver of Huadong Medicine's success, displaying substantial progress in 2023. The industrial sector generated sales revenue of 12.217 billion yuan, representing a remarkable growth rate of 9.45%. The net profit attributable to shareholders in this sector soared to an impressive 2.33 billion yuan, with a net asset return rate of 23.98%. Huadong Medicine's focus on endocrinology, immunology, and oncology yielded fruitful outcomes in 2023.

In the field of endocrinology, Huadong Medicine concentrated its efforts on the GLP-1 receptor target, resulting in the development of a comprehensive pipeline of innovative drugs and biosimilars. Notably, the company obtained regulatory approval for the domestically produced Liraglutide, a GLP-1 receptor agonist, for both diabetes and weight management indications. Furthermore, their orally administered small molecule GLP-1 receptor agonist, HDM1002, received dual IND approvals from China and the United States, demonstrating the company's commitment to advancing treatments for diabetes and obesity.

Huadong Medicine's research center also made significant strides in the field of immunology, with a portfolio of over ten innovative biologics and small molecule products under development. The company obtained acceptance for the market approval application of HDM3001 (QX001S), a biologic drug for plaque psoriasis. Additionally, Huadong Medicine expanded its portfolio of topical formulations by introducing innovative products such as ZORYVE® lotion and foam, as well as Wynzora® lotion. The company's efforts to address unmet medical needs were further exemplified by the acceptance of their application for Arcalyst® injection, a treatment for cold autoinflammatory syndrome and recurrent pericarditis, both of which are classified as rare diseases.

In the field of oncology, Huadong Medicine focused on advancing its antibody-drug conjugate (ADC) pipeline while collaborating with leading domestic biotechnology companies. The company submitted an IND application for HDM2005, its first internally developed ADC project for the treatment of advanced solid tumors and hematological malignancies. Additionally, the company initiated IND studies for HDM2006, a small molecule anticancer drug and the first HPK-1 PROTAC (Hematopoietic progenitor kinase 1 protein degrader) developed in-house. Huadong Medicine also secured the rights to market ELAHERE®, a first-in-class ADC therapy for ovarian cancer, further enriching its oncology product portfolio.

Huadong Medicine has achieved significant growth and success in 2023, with its annual revenue reaching an impressive 40.6 billion yuan. The company's robust performance in the pharmaceutical industry underscores its commitment to innovation and the development of breakthrough therapies in endocrinology, immunology, and oncology. With a strong pipeline of over 60 innovative products, Huadong Medicine is poised for continued growth and contributions to the advancement of healthcare.

https://www.echemi.com/shop-us20230919080905887/index.html